Company news
BioCryst Pharmaceuticals, Inc. news in 2019
BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks
December 10, 2019
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
November 17, 2019
BioCryst Prices Public Offering of Common Stock
November 12, 2019
BioCryst Commences Public Offering of Common Stock
November 11, 2019
BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones
November 5, 2019
BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks
November 4, 2019
BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva
October 31, 2019
BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
October 27, 2019
U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile
September 25, 2019
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
September 22, 2019